Correction to: Pharmacokinetic and Pharmacodynamic Studies of Elacestrant, A Novel Oral Selective Estrogen Receptor Degr
- PDF / 523,788 Bytes
- 2 Pages / 595.276 x 790.866 pts Page_size
- 31 Downloads / 205 Views
CORRECTION
Correction to: Pharmacokinetic and Pharmacodynamic Studies of Elacestrant, A Novel Oral Selective Estrogen Receptor Degrader, in Healthy Post‑Menopausal Women Maureen G. Conlan1 · Erik F. J. de Vries2 · AWJM Glaudemans2 · Yamei Wang3 · Steven Troy4
© The Author(s) 2020
Correction to: European Journal of Drug Metabolism and Pharmacokinetics https://doi.org/10.1007/s13318-020-00635-3
Authors would like to correct the errors in table 2. Corrected version of Table 2 given below. The original article has been corrected.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The original article can be found online at https://doi.org/10.1007/ s13318-020-00635-3. * Maureen G. Conlan [email protected] 1
Department of Oncology Clinical Development, Radius Health, Inc., 950 Winter Street, Waltham, MA 02451, USA
2
Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
3
Department of Biostatistics, Radius Health, Inc., 950 Winter Street, Waltham, MA, USA
4
Department of Clinical Pharmacology, Radius Health, Inc., 950 Winter Street, Waltham, MA, USA
Vol.:(0123456789)
M. G. Conlan et al.
Table 2 Pharmacokinetic parameters of elacestrant in Study 001 and Study 004 Study 001 SAD parta
Cmax (ng/ml) tmax (h)
AUC0–last (ng·h/ml) AUC0–∞ (ng·h/ml) t1/2 (h)
CL/F (l/h)
Vz/F (l)
1 mg IV (n = 5) 1 mg (n = 2)b 10 mg (n = 6) 25 mg (n = 6) 50 mg (n = 6) 50 mg fed (n = 6) 100 mg (n = 6) 200 mg (n = 6)
69.8 ± 30.7 0.06 ± 0.02 0.7 ± 0.4 1.8 ± 0.5 3.4 ± 0.7 7.0 ± 1.5 11.8 ± 2.0 31.5 ± 5.6
23.9 ± 3.6 NR 13.1 ± 9.4 32.2 ± 15.7 61.3 ± 11.7 96.8 ± 20.0 247 ± 71.9 649 ± 183
28.0 ± 5.2 NR 16.8 ± 11.7 40.6 ± 21.6 73.3 ± 13.2 116 ± 26.9 294 ± 80.8 774 ± 239
33.4 ± 6.2 NR 31.9 ± 8.1 32.5 ± 6.0 29.1 ± 3.4 28.8 ± 2.7 28.4 ± 3.9 27.4 ± 3.7
36.8 ± 7.7d NR 760 ± 323 786 ± 419 702 ± 134 451 ± 111 361 ± 92 281 ± 90
1730 ± 155e NR 33,700 ± 13,800 34,500 ± 13,300 29,800 ± 8910 18,500 ± 3050 14,900 ± 4920 10,800 ± 2860
MAD parta
Cmax (ng/ml) tmax (h)
AUC0–τ (ng·h/ml)
Rac
t1/2 (h)
CLss/F (l/h) Vz/F (l)
10 mg/day (n = 7)—day 1 Day 7 25 mg/day (n = 7)c—day 1 Day 7 50 mg/day (n = 8)—day 1 Day 7 100
Data Loading...
